Price
No data yet.
Social Signal Score
Analyst Ratings
1 analystRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Timothy Warbington
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 4
- Beta
- 1.90
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -10.45
Financials
Revenue
$0.00-100.0%Net Income
$-1.51MEBITDA
$-1.54MFree Cash Flow
$-1.47MEPS (diluted)
$-0.41Shares Outstanding (diluted)
3.70M+2741876.3%Operating Expenses
$1.54MCash & Debt
$8.71MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $6.0K | $-6.00M | $-2.52 |
| 2024 | $11.0K | $-5.49M | $-3.71 |
| 2023 | $9.0K | $-5.29M | $-3.76 |
| 2022 | $88.6K | $-10.14M | $-9.28 |
| 2021 | $87.8K | $19.21M | $73.75 |
| 2020 | $164.5K | $-36.33M | $-626.88 |
| 2019 | $165.5K | $-8.48M | $-5017.67 |
| 2018 | $124.4K | $-13.66M | $-11351.33 |
| 2017 | $4.8K | $-2.66M | $-17379.79 |
| 2016 | $0.00 | $-766.1K | $-5471.94 |
| 2015 | $0.00 | $-30.8K | $-1281.71 |
| 2014 | $0.00 | $-28.0K | $-1167.17 |
| 2013 | $0.00 | $-27.3K | $-1136.75 |
| 2012 | $0.00 | $-25.6K | $-1066.04 |
Valuation
CELZhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
80+0.00%Social Signal Score
Mentions (3)
- Newsglobenewswire.com·7h ago·Negative
…duction in Average Pain Scores in Ultrasome™ Knee Osteoarthritis Study PHOENIX, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) ("Creative Medical" or the "Company"), a clinical-stage biotechnology company advancing regenerative medicine technologies, today highlighted additional clinical and laboratory findings for Ultrasome™, its investigational cell-free regenerative medicine platform, following a presentation at the Annual Meeting of Experts in Cel…
View source ↗ - Newsglobenewswire.com·33d ago·Neutral
…tellectual Property Portfolio with New U.S. Provisional Patent Filing PHOENIX, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) ("Creative Medical" or the "Company"), a clinical-stage biotechnology company advancing regenerative medicine solutions, today announced the filing of a new U.S. provisional patent application designed to expand intellectual property protection surrounding Ultrasome™, the Company's proprietary cell-free regenerative medicine p…
View source ↗ - Newsglobenewswire.com·61d ago·Negative
Creative Medical Technology Holdings Successfully Completes Enrollment and Treatment Across Entire FDA-Cleared ADAPT Trial, Including Opioid Cohort, Advancing CELZ-201 / Olastrocel Toward RMAT Evaluation and Phase 3 Planning All patients enrolled and treated across original and FDA-cleared expansion cohorts Positive safety and early efficacy signals continue to support late-stage development planning for Olastrocel in chronic lower back pain With enrollment and treatment completed, ADAPT-related…
View source ↗
Earnings
Fri, Nov 6(in 2 weeks)
Consensus estimate $-0.24 per share
Typical surprise -5.1% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Aug 7$-0.41 vs $-0.39miss
- Fri, May 8$-0.38 vs $-0.39beat
- Fri, Mar 20$-0.80 vs $-0.37miss
- Fri, Nov 7$-0.48 vs $-0.48beat
- Fri, Aug 8$-0.48 vs $-0.63beat
- Fri, May 9$-0.83 vs $-0.52miss
Estimates and results for CELZ via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CELZ officers and directors.
- Bought
- $266k
- Sold
- $75.5bn
26 trades
24 trades
- Finger Michael H.sold
- Finger Michael H.sold
- Warbington Timothybought
- Warbington Timothybought
- Warbington Timothybought
- Warbington Timothybought
- Warbington Timothybought
- Warbington Timothybought
49 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in CELZ.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.